Please assess the completion status of the following clinical trial:

Trial Title: Electroacupuncture Combined With Antidepressants for Post-stroke Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* most recently experience an ischemic or hemorrhagic stroke, documented by cerebral computed topographic scanning or magnetic resonance imaging~* develop significant depression, with a HAMD-17 score of 16 or greater~Exclusion Criteria:~* presence of severe aphasia, especially fluent aphasia~* presence of severe cognitive dysfunction, indicated the Mini-mental State Examination (MMSE) score of \< 18~* had a history of psychiatric illness other than depression~* presence of another chronic disorder, including severe Parkinson's disease, cardiac disease, cancers, epilepsy, or chronic alcoholism~* impaired hepatic or renal function~* have bleeding tendency

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- DCEAS (Type: EXPERIMENTAL): Body electroacupuncture plus dense cranial electroacupuncture stimulation (DCEAS)~For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day.
- n-CEA (Type: PLACEBO_COMPARATOR): Body electroacupuncture plus non-invasive cranial electroacupuncture (n-CEA)~For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day.

Based on this trial design, predict the completion outcome and termination type (if applicable).